Developer docs
API playgroundTry for free, no card

Search company profiles

Blackrock Neurotech

Full company profile

uuid0000c92

Namestring
Blackrock Neurotech
Legal namestring
Blackrock Microsystems Inc.
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Blackrock Neurotech (legal name Blackrock Microsystems Inc., DBA Blackrock Neurotech) is a privately held brain-computer interface company founded in 2008 and headquartered in Salt Lake City, Utah, with a regional office in Hanover, Germany. The company designs and manufactures implantable microelectrode arrays — anchored by its FDA 510(k)-cleared Utah Array / NeuroPort Electrode and supporting data acquisition hardware (NeuroPort NSP, NeuroPlex E, Cerebus, CerePlex Direct, CereStim R96) — that record and stimulate neural activity at single-neuron resolution. Its products are used by more than 1,000 research institutions across 53 countries and have been deployed in 38 of the 67 global intracortical BCI clinical-trial participants, accumulating more than 30,000 days of in-patient implant data with zero FDA-reported serious adverse events.

The company's commercial strategy operates on two tracks. First, it sells research-use hardware, headstages, software (Central, cbSDK, brPY, CereStim API) and licensing of electrode know-how to academic and medical-research customers, generating the bulk of current revenue through enterprise field sales. Second, it is transitioning to a regulated medical-device business via the MoveAgain BCI Platform — which received FDA Breakthrough Device Designation in 2021 — to serve patients with paralysis, ALS, and other neurological disorders, with future product lines including the patent-pending Neuralace 10,000+ channel flexible interface and a speech-decoding BCI. In April 2024, Tether Evo acquired a controlling stake through a $200 million investment to accelerate this commercialization, and the company has added scaled medical-device leadership (CTO Jeff C. Jensen, CFO Nathan A. Smith) and clinical-trial partnerships (University of Pittsburgh RNEL, Caltech, Stanford, BrainGate2) to support the pivot.

Short descriptiontext

Blackrock Neurotech is a private Salt Lake City-based brain-computer interface company developing FDA-cleared implantable microelectrode arrays and neural data-acquisition systems. It supplies 1,000+ neuroscience research laboratories globally and is commercializing the MoveAgain BCI platform for paralysis patients following a $200 million Tether investment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brain-computer interface, implantable neural devices, neurophysiology research tools, microelectrode arrays, neural signal processors
Industry3 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Brain-Computer Interface Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Research Products Sales
TypeHardware Sales
Description

Sale of neurophysiology research tools including electrode arrays, headstages, data acquisition systems, and stimulators to research institutions and universities worldwide. Products include Utah Array, NeuroPort, Cerebus, CerePlex, CereStim, and NeuroSnap product lines.

nexdigm.com
2MoveAgain Commercial BCI Platform
TypeOne Time License
Description

Planned commercialization of the MoveAgain BCI platform as a medical device for patients with paralysis. Received FDA Breakthrough Designation in 2021 and aims to be commercially available to broader patient population.

blackrockneurotech.com
3Licensing and Technology Transfer
TypeLicensing Royalties
Description

Licensing of proprietary electrode technology and BCI know-how to research institutions and clinical partners. Technology developed with and licensed from University of Utah and other academic partners.

blackrockneurotech.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Blackrock Neurotech develops and manufactures implantable brain-computer interface (BCI) technology, including microelectrode arrays, neural signal processors, digital headstages, and stimulators used by research institutions worldwide. The company is also commercializing the MoveAgain BCI platform, an FDA Breakthrough Device-designated medical device enabling patients with paralysis to control digital devices by thought.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 30,000+ days of safe in-patient BCI research with zero FDA-reported serious adverse events
+5 more records
Product overview1 text field

Blackrock Neurotech offers a comprehensive neurotechnology platform centered on implantable brain-computer interface systems. The core portfolio includes the NeuroPort System (FDA-cleared neural signal processor), NeuroPlex E digital headstage (FDA-cleared), Utah Array and NeuroPort Electrode 96 (gold-standard microelectrode arrays), CereStim R96 neurostimulator, and Cerebus/CerePlex Direct data acquisition systems. Supporting products include NeuroSnap clinical headstages (A8, D), NeuroSnap Bridge and Splitter Box for clinical research integration, and Noldus EthoVision XT behavioral tracking integration. The MoveAgain BCI Platform represents the company's first commercial product targeting patients with paralysis, while Neuralace (10,000+ channel next-generation interface) is in development. The platform enables applications in motor restoration, speech decoding, sensory feedback, and neuroprosthetics through proprietary neural signal processing and decoding algorithms.

Product and service8 records
1Utah Array
CategoryMicroelectrode Arrays
Description

High-channel-count microelectrode array with up to 128 electrodes per array used for cortical recording and stimulation in neuroscience research.

2NeuroPort Electrode 96
CategoryMicroelectrode Arrays
Description

FDA 510(k)-cleared microelectrode array for human neural recording, the only FDA-cleared microelectrode array capable of recording hundreds of neurons from the human cortex.

3NeuroPort System
CategoryNeural Signal Processors
Description

FDA-cleared biopotential signal processing system that records from 32 to 512 channels with real-time deterministic closed-loop capabilities for human BCI applications.

4NeuroPlex E
CategoryDigital Headstages
Description

FDA-cleared next-generation digital headstage providing noise-free high-fidelity transmission and recording of extracellular spikes and local field potentials with 128 channels at 16-bit resolution.

5CerePlex Direct
CategoryData Acquisition Systems
Description

Cost-effective MRI-compatible data acquisition system delivering low-noise neural signal recording in a plug-and-play package, supporting up to 256 channels.

6Cerebus Neural Signal Processor
CategoryData Acquisition Systems
Description

Highly-configurable multichannel data acquisition system for animal neurophysiology experiments with closed-loop capabilities and up to 512 channel recording.

7CereStim R96
CategoryNeurostimulators
Description

Fully programmable 96-channel neurostimulator with current-controlled biphasic charge-balanced rectangular stimulation, capable of producing up to 16 simultaneous stimuli from 100μA to 10mA.

8MoveAgain BCI Platform
CategoryCommercial BCI Platforms
Description

First commercial implantable BCI platform enabling patients with paralysis to control digital devices and interact with computers by thinking. FDA Breakthrough Device Designation received in 2021.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-14
Description

Distribution agreement for Axon-R, a non-invasive multi-modal BCI research technology. This partnership expands access to non-invasive BCI research capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-08
Description

Official collaboration announced at Society for Neuroscience 2024 (#SfN24) integrating Noldus EthoVision XT behavioral tracking software with Blackrock's electrophysiology systems. The integration enables real-time synchronization of neural activity and behavioral data, creating a unified platform for behavioral and neural research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-21
Description

Partnership to expand BCI clinical trials with in-home portable system, extending geographic reach and number of participants. Pitt RNEL is scaling future BCI studies enabling more people with paralysis to participate from their homes. Pitt was among the first research centers to implant Blackrock's BCI in human participants.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-05-26
Description

Collaboration to advance training and calibration in the MoveAgain BCI platform. AE Studio, which won the Neural Latents Benchmark Challenge with their AE Decoder Solution, is developing improved machine learning models and algorithms to decrease calibration requirements and improve user experience for paralyzed patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with industry leader ClearPoint Neuro to develop custom navigation solutions including consumables, hardware, software and robotics to streamline and scale BCI implantation while reducing surgical complications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration for neural implant studies including Galen Buckwalter and James Johnson studies. Galen Buckwalter received six Utah arrays across motor, sensory, and frontal cortices as part of Caltech-led study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Caltech for neural implant studies. Galen Buckwalter study involves NIH-funded research on neural prostheses for spinal cord injuries conducted by Caltech and USC under Dr. Richard Andersen.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Blackrock Neurotech contributes 96-channel microelectrode arrays to the BrainGate2 clinical trial, which made precise decoding of neural signals possible for research including Stanford University finger decoding studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial collaboration where Ian Burkhart became the first person to use a BCI implant to control muscle stimulation for hand movements. This groundbreaking trial demonstrated restoration of voluntary muscle control.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Emerging implantable BCI company developing high-data-rate Connexus interface for medical and eventually consumer applications. Directly comparable as a next-generation intracortical BCI competitor pursuing FDA pathway.

TypeDirect peer
Description

Elon Musk-backed implantable BCI company developing the N1 chip and R1 surgical robot. Competes head-to-head with Blackrock's Utah Array and MoveAgain platform for human intracortical BCI applications in paralysis and beyond.

TypeDirect peer
Description

Endovascular BCI company whose Stentrode device is delivered via blood vessels, avoiding open brain surgery. A direct competitor in motor/communication restoration for paralysis patients, with FDA breakthrough designation and implanted patients in the US/Australia.

TypeDirect peer
Description

BCI company developing the Layer 7 cortical interface, a thin-film electrode array designed for high-resolution recording. Targets both clinical applications and eventual consumer use, directly competing in intracortical BCI space.

TypeBroad incumbent
Description

Largest neuromodulation incumbent with Activa PC DBS, Intellis SCS, and Percept PC with BrainSense. Has the manufacturing scale, FDA infrastructure, and neurosurgeon relationships that any commercial BCI must eventually navigate; potential acquirer or competitor in adjacent indications.

6Abbott
TypeBroad incumbent
Description

Through its St. Jude acquisition, Abbott markets the Infinity DBS and Proclaim SCS systems for neuromodulation. A broad incumbent in implantable neuro devices with established reimbursement and clinical workflows that overlap with Blackrock's MoveAgain commercial targets.

TypeBroad incumbent
Description

Markets the Vercise DBS and WaveWriter SCS systems and is actively investing in next-gen neuromodulation including brain-computer interface research. A broad incumbent competitor with deep neurosurgery channel access.

TypeEmerging player
Description

Non-invasive BCI company developing the Axon-R wearable and previously the AXON-R/Talker AAC device. Already in distribution partnership with Blackrock for Axon-R, making it both a partner and a non-invasive competitor for communication restoration in paralysis/ALS.

TypeOthers
Description

MRI-guided neurosurgical navigation and drug delivery company that partners with Blackrock on implantation workflows. Acts as the enabling surgical infrastructure layer for Blackrock's commercial BCI rollout rather than a direct competitor.

TypeOthers
Description

Academic consortium conducting the longest-running intracortical BCI clinical trials, including BrainGate2 which uses Blackrock's Utah Array. Functions as both a critical clinical evidence generator and the de facto research-validation channel for Blackrock's implant technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blackrock Neurotech

Brain-Computer Interface Technologyblackrockneurotech.com

Blackrock Neurotech is a private Salt Lake City-based brain-computer interface company developing FDA-cleared implantable microelectrode arrays and neural data-acquisition systems. It supplies 1,000+ neuroscience research laboratories globally and is commercializing the MoveAgain BCI platform for paralysis patients following a $200 million Tether investment.

What Blackrock Neurotech does

Blackrock Neurotech (legal name Blackrock Microsystems Inc., DBA Blackrock Neurotech) is a privately held brain-computer interface company founded in 2008 and headquartered in Salt Lake City, Utah, with a regional office in Hanover, Germany. The company designs and manufactures implantable microelectrode arrays — anchored by its FDA 510(k)-cleared Utah Array / NeuroPort Electrode and supporting data acquisition hardware (NeuroPort NSP, NeuroPlex E, Cerebus, CerePlex Direct, CereStim R96) — that record and stimulate neural activity at single-neuron resolution. Its products are used by more than 1,000 research institutions across 53 countries and have been deployed in 38 of the 67 global intracortical BCI clinical-trial participants, accumulating more than 30,000 days of in-patient implant data with zero FDA-reported serious adverse events.

The company's commercial strategy operates on two tracks. First, it sells research-use hardware, headstages, software (Central, cbSDK, brPY, CereStim API) and licensing of electrode know-how to academic and medical-research customers, generating the bulk of current revenue through enterprise field sales. Second, it is transitioning to a regulated medical-device business via the MoveAgain BCI Platform — which received FDA Breakthrough Device Designation in 2021 — to serve patients with paralysis, ALS, and other neurological disorders, with future product lines including the patent-pending Neuralace 10,000+ channel flexible interface and a speech-decoding BCI. In April 2024, Tether Evo acquired a controlling stake through a $200 million investment to accelerate this commercialization, and the company has added scaled medical-device leadership (CTO Jeff C. Jensen, CFO Nathan A. Smith) and clinical-trial partnerships (University of Pittsburgh RNEL, Caltech, Stanford, BrainGate2) to support the pivot.

Blackrock Neurotech firmographics

Firmographics
Name
Blackrock Neurotech
Legal name
Blackrock Microsystems Inc.
Website
https://blackrockneurotech.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
101–250 employees
Short description
Blackrock Neurotech is a private Salt Lake City-based brain-computer interface company developing FDA-cleared implantable microelectrode arrays and neural data-acquisition systems. It supplies 1,000+ neuroscience research laboratories globally and is commercializing the MoveAgain BCI platform for paralysis patients following a $200 million Tether investment.
Ownership category
akta.pro rank

Blackrock Neurotech industry classification

Industry
Product category
Brain-Computer Interface Technology
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Brain-computer interface
  • Implantable neural devices
  • Neurophysiology research tools
  • Microelectrode arrays
  • Neural signal processors

Where Blackrock Neurotech is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Blackrock Neurotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Research Products Sales: Sale of neurophysiology research tools including electrode arrays, headstages, data acquisition systems, and stimulators to research institutions and universities worldwide. Products include Utah Array, NeuroPort, Cerebus, CerePlex, CereStim, and NeuroSnap product lines.
  2. MoveAgain Commercial BCI Platform: Planned commercialization of the MoveAgain BCI platform as a medical device for patients with paralysis. Received FDA Breakthrough Designation in 2021 and aims to be commercially available to broader patient population.
  3. Licensing and Technology Transfer: Licensing of proprietary electrode technology and BCI know-how to research institutions and clinical partners. Technology developed with and licensed from University of Utah and other academic partners.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Blackrock Neurotech product offering

Product offering

Core offering

Blackrock Neurotech develops and manufactures implantable brain-computer interface (BCI) technology, including microelectrode arrays, neural signal processors, digital headstages, and stimulators used by research institutions worldwide. The company is also commercializing the MoveAgain BCI platform, an FDA Breakthrough Device-designated medical device enabling patients with paralysis to control digital devices by thought.

Product overview

Blackrock Neurotech offers a comprehensive neurotechnology platform centered on implantable brain-computer interface systems. The core portfolio includes the NeuroPort System (FDA-cleared neural signal processor), NeuroPlex E digital headstage (FDA-cleared), Utah Array and NeuroPort Electrode 96 (gold-standard microelectrode arrays), CereStim R96 neurostimulator, and Cerebus/CerePlex Direct data acquisition systems. Supporting products include NeuroSnap clinical headstages (A8, D), NeuroSnap Bridge and Splitter Box for clinical research integration, and Noldus EthoVision XT behavioral tracking integration. The MoveAgain BCI Platform represents the company's first commercial product targeting patients with paralysis, while Neuralace (10,000+ channel next-generation interface) is in development. The platform enables applications in motor restoration, speech decoding, sensory feedback, and neuroprosthetics through proprietary neural signal processing and decoding algorithms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Utah Array High-channel-count microelectrode array with up to 128 electrodes per array used for cortical recording and stimulation in neuroscience research.
  • NeuroPort Electrode 96 FDA 510(k)-cleared microelectrode array for human neural recording, the only FDA-cleared microelectrode array capable of recording hundreds of neurons from the human cortex.
  • NeuroPort System FDA-cleared biopotential signal processing system that records from 32 to 512 channels with real-time deterministic closed-loop capabilities for human BCI applications.
  • NeuroPlex E FDA-cleared next-generation digital headstage providing noise-free high-fidelity transmission and recording of extracellular spikes and local field potentials with 128 channels at 16-bit resolution.
  • CerePlex Direct Cost-effective MRI-compatible data acquisition system delivering low-noise neural signal recording in a plug-and-play package, supporting up to 256 channels.
  • Cerebus Neural Signal Processor Highly-configurable multichannel data acquisition system for animal neurophysiology experiments with closed-loop capabilities and up to 512 channel recording.
  • CereStim R96 Fully programmable 96-channel neurostimulator with current-controlled biphasic charge-balanced rectangular stimulation, capable of producing up to 16 simultaneous stimuli from 100μA to 10mA.
  • MoveAgain BCI Platform First commercial implantable BCI platform enabling patients with paralysis to control digital devices and interact with computers by thinking. FDA Breakthrough Device Designation received in 2021.

Quantifiable outcome

  • 30,000+ days of safe in-patient BCI research with zero FDA-reported serious adverse events
  • +5 more outcomes

Companies that use Blackrock Neurotech

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Blackrock Neurotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature11 records

Blackrock Neurotech partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • CognixionminorChannel Partner/ Reseller/ Distributor · 14 May 2025Distribution agreement for Axon-R, a non-invasive multi-modal BCI research technology. This partnership expands access to non-invasive BCI research capabilities.
  • Noldus Information TechnologycoreTechnology or Integration · 8 October 2024Official collaboration announced at Society for Neuroscience 2024 (#SfN24) integrating Noldus EthoVision XT behavioral tracking software with Blackrock's electrophysiology systems. The integration enables real-time synchronization of neural activity and behavioral data, creating a unified platform for behavioral and neural research.
  • University of Pittsburgh Rehab Neural Engineering Labs (RNEL)coreStrategic or Co-development Partner · 21 June 2022Partnership to expand BCI clinical trials with in-home portable system, extending geographic reach and number of participants. Pitt RNEL is scaling future BCI studies enabling more people with paralysis to participate from their homes. Pitt was among the first research centers to implant Blackrock's BCI in human participants.
  • AE StudiominorStrategic or Co-development Partner · 26 May 2022Collaboration to advance training and calibration in the MoveAgain BCI platform. AE Studio, which won the Neural Latents Benchmark Challenge with their AE Decoder Solution, is developing improved machine learning models and algorithms to decrease calibration requirements and improve user experience for paralyzed patients.
  • ClearPoint NeurocoreStrategic or Co-development PartnerPartnership with industry leader ClearPoint Neuro to develop custom navigation solutions including consumables, hardware, software and robotics to streamline and scale BCI implantation while reducing surgical complications.
  • Caltech Andersen LabcoreStrategic or Co-development PartnerResearch collaboration for neural implant studies including Galen Buckwalter and James Johnson studies. Galen Buckwalter received six Utah arrays across motor, sensory, and frontal cortices as part of Caltech-led study.
  • University of Southern California (USC)coreStrategic or Co-development PartnerResearch collaboration with Caltech for neural implant studies. Galen Buckwalter study involves NIH-funded research on neural prostheses for spinal cord injuries conducted by Caltech and USC under Dr. Richard Andersen.
  • BrainGate2 Clinical TrialcoreStrategic or Co-development PartnerBlackrock Neurotech contributes 96-channel microelectrode arrays to the BrainGate2 clinical trial, which made precise decoding of neural signals possible for research including Stanford University finger decoding studies.
  • Battelle and The Ohio State University Wexner Medical CentercoreStrategic or Co-development PartnerClinical trial collaboration where Ian Burkhart became the first person to use a BCI implant to control muscle stimulation for hand movements. This groundbreaking trial demonstrated restoration of voluntary muscle control.

Scale indicators13 records

Recent moves7 records

Expansion highlights8 records

Blackrock Neurotech competitors and assessment

Company assessment

Direct peers

  • Paradromics: Emerging implantable BCI company developing high-data-rate Connexus interface for medical and eventually consumer applications. Directly comparable as a next-generation intracortical BCI competitor pursuing FDA pathway.
  • Neuralink: Elon Musk-backed implantable BCI company developing the N1 chip and R1 surgical robot. Competes head-to-head with Blackrock's Utah Array and MoveAgain platform for human intracortical BCI applications in paralysis and beyond.
  • Synchron: Endovascular BCI company whose Stentrode device is delivered via blood vessels, avoiding open brain surgery. A direct competitor in motor/communication restoration for paralysis patients, with FDA breakthrough designation and implanted patients in the US/Australia.
  • Precision Neuroscience: BCI company developing the Layer 7 cortical interface, a thin-film electrode array designed for high-resolution recording. Targets both clinical applications and eventual consumer use, directly competing in intracortical BCI space.

Broad incumbents

  • Medtronic: Largest neuromodulation incumbent with Activa PC DBS, Intellis SCS, and Percept PC with BrainSense. Has the manufacturing scale, FDA infrastructure, and neurosurgeon relationships that any commercial BCI must eventually navigate; potential acquirer or competitor in adjacent indications.
  • Abbott: Through its St. Jude acquisition, Abbott markets the Infinity DBS and Proclaim SCS systems for neuromodulation. A broad incumbent in implantable neuro devices with established reimbursement and clinical workflows that overlap with Blackrock's MoveAgain commercial targets.
  • Boston Scientific: Markets the Vercise DBS and WaveWriter SCS systems and is actively investing in next-gen neuromodulation including brain-computer interface research. A broad incumbent competitor with deep neurosurgery channel access.

Emerging players

  • Cognixion: Non-invasive BCI company developing the Axon-R wearable and previously the AXON-R/Talker AAC device. Already in distribution partnership with Blackrock for Axon-R, making it both a partner and a non-invasive competitor for communication restoration in paralysis/ALS.

Others

  • ClearPoint Neuro: MRI-guided neurosurgical navigation and drug delivery company that partners with Blackrock on implantation workflows. Acts as the enabling surgical infrastructure layer for Blackrock's commercial BCI rollout rather than a direct competitor.
  • BrainGate: Academic consortium conducting the longest-running intracortical BCI clinical trials, including BrainGate2 which uses Blackrock's Utah Array. Functions as both a critical clinical evidence generator and the de facto research-validation channel for Blackrock's implant technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Blackrock Neurotech social profiles

Digital presence

Blackrock Neurotech compliance and trust

Trust signal

Compliance8 records

Blackrock Neurotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blackrock Neurotech leadership team

Management profile

Number of profiles

Profiles5 records

Blackrock Neurotech funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blackrock Neurotech M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blackrock Neurotech

What does Blackrock Neurotech do?

Blackrock Neurotech develops and manufactures implantable brain-computer interface (BCI) technology, including microelectrode arrays, neural signal processors, digital headstages, and stimulators used by research institutions worldwide. The company is also commercializing the MoveAgain BCI platform, an FDA Breakthrough Device-designated medical device enabling patients with paralysis to control digital devices by thought.

Is Blackrock Neurotech a public or private company?

Blackrock Neurotech is a private company. It is classified as corporate owned and is currently operating.

When was Blackrock Neurotech founded?

Blackrock Neurotech was founded in 2008. It employs 101 to 250 people.

Where is Blackrock Neurotech based?

Blackrock Neurotech is headquartered in Salt Lake City, United States, in the North America region.

How does Blackrock Neurotech make money?

Three revenue lines are on record. Research Products Sales are the primary driver. The others are moveAgain Commercial BCI Platform and licensing and Technology Transfer.

Who are Blackrock Neurotech's main competitors?

Direct peers on record are Paradromics, Neuralink, Synchron and Precision Neuroscience. Broad incumbents are Medtronic, Abbott and Boston Scientific. Cognixion is listed as an emerging player. Others are ClearPoint Neuro and BrainGate.

Does Blackrock Neurotech have an API?

No public API is recorded for Blackrock Neurotech.

What industry is Blackrock Neurotech in?

Blackrock Neurotech's product category is Brain-Computer Interface Technology. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScienmagNew iridium oxide metallization quadruples stimulation lifetime of UtahA study in Bioelectronic Medicine found that a new iridium oxide metallization for Utah electrode arrays survived 4 million high-current stimulation pulses without failure, while standard Blackrock metallization failed in about half of its electrodes at 1 million pulses. The research metallization used a pure platinum layer annealed in oxygen, and the team notes the test exceeds safe physiological conditions.PrtimesNeuroplasticity Therapy Market Size, Share, Trends & Growth Forecast 2035 – PR TimesA market report by Wise Guys Report values the Neuroplasticity Therapy Market at USD 5.4 billion in 2024, projecting growth to USD 10.2 billion by 2035 with a CAGR of 6.0%. The expansion is driven by rising neurological disorders, technological advancements in rehabilitation, and increasing demand for personalized treatments. Key players such as Medtronic, Boston Scientific, and Blackrock Neurotech are contributing to the development of neurostimulation and digital rehabilitation technologies.FinanzNachrichten.deDer Hirnchip-Pionier: 100.000 Elektroden im Kopf und die Frage, die alles veränderteBlackrock Neurotech, led by CEO Marcus Gerhardt, has implanted brain-computer interfaces in 56 people and collected significant neural data while shifting its strategic focus from treating paralyzed patients to developing devices for healthy individuals. The company is addressing key technical challenges such as reducing calibration time and navigating FDA regulatory hurdles regarding new materials, with a goal of achieving broader market approval within a five-year horizon.FinanzNachrichten.deThe Brain Implant Pioneer: 100,000 electrodes in the brain and the question that changed everythingBlackrock Neurotech, led by CEO Marcus Gerhardt, has implanted 56 people and gathered 55,000 patient days of brain data, positioning itself as a leader in brain-computer interface technology. The company is developing next-generation platforms designed for able-bodied individuals and claims to have reduced calibration time from nine months to minutes using its Utah array technology. Blackrock Neurotech continues to pursue FDA clearance while comparing its capabilities against competitors like Neuralink.The RegisterAI and brain-computer interface allow speechless ALS patient to work a full-time jobA UC Davis research team developed a brain-computer interface system using machine learning that enabled ALS patient Casey Harrell to communicate with 92% accuracy in daily use outside a laboratory setting, allowing him to work full-time as an environmental advocate. The system, which has operated reliably for over 3,800 hours since 2023, achieved 99% accuracy in controlled tests and uses Blackrock Neurotech hardware with the team's own BRAND software platform. The researchers say this demonstrates that BCI technology can transition from laboratory experiments to practical, everyday applications for people with paralysis and speech impairments.TheconversationBrain implants allow us to move and talk. But they could also be hackedThis article examines brain-computer interface technology, which reads electrical signals from the brain and translates them into digital commands to help patients with paralysis, stroke, and other neurological conditions move and communicate. Three companies—Blackrock Neurotech, Synchron, and Neuralink—are racing to bring invasive brain implants to market, with the global market projected to grow from under $3 billion to approximately A$14 billion by 2033. The article outlines key risks including physical harm from implants, cybersecurity vulnerabilities that could expose neural data or manipulate motor functions, and unequal access due to costs ranging from $50,000 to $140,000 per device.The Jerusalem PostThis hat knows how to read your thoughts – and perform actionsStartup company Sabi has developed a non-invasive brain-computer interface in the form of a hat equipped with 70 to 100 thousand sensors, capable of translating the user's motor intent into text on a screen without surgical implantation. The technology aims to reach market by the end of the year and could offer a safer, more accessible alternative to invasive BCI methods such as Neuralink and Blackrock Neurotech implants. The scientific community remains cautious, with Synchron's CEO noting that achieving real-time accuracy through a wearable device faces significant technological challenges due to the physical barrier of the skull and hair.New York PostTech company claims its new caps and beanies can read your mind and put it on a screen — no brain implant requiredSabi, a tech company led by CEO Rahul Chhabra, claims to have developed a non-invasive brain-computer interface in the form of beanies and caps containing 70,000 to 100,000 sensors that read neural activity and translate thought directly into text on a computer screen. The company says the device will be on the market by the end of the year, though no independent testing has been conducted and access has been limited to investors. The article contextualizes this against established invasive BCI competitors including Neuralink, Blackrock Neurotech, and Synchron, all of which require surgical or vascular procedures to implant chips in or near the brain.Tracxn2026 Funding Rounds & List of InvestorsBlackrock Neurotech has undergone multiple funding rounds since 2009, with the most recent being a grant in May 2025. The company has received funding from various sources including government-backed grants and investment rounds, and has experienced significant fluctuations in valuation.